Hmg-coa reductase - Open Access .click

Results 1 to 10 of about 36,764 (181)

The Journal of Japan Atherosclerosis Society, 2001
Publisher Summary This chapter focuses on the 3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase enzyme that is known as the rate limiting enzyme in the cholesterol biosynthetic pathway. Today, HMG-CoA reductase inhibitors (statins) account for the large majority of prescriptions for lipid-lowering drugs in most countries.
D R, Illingworth, J A, Tobert
+7 more sources

HMG-CoA reductase inhibitors and the kidney [PDF]

Kidney International, 2007
During the last two decades, numerous studies have demonstrated that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) diminish the risk of cardiovascular morbidity and mortality. Although these studies have focused primarily on the ability of statins to lower circulating levels of low-density lipoprotein cholesterol, more recent ...
Campese, V.-M., Park, J.
openaire +2 more sources

Comparing HMG-CoA reductase inhibitors [PDF]

Clinical Cardiology, 2003
The statins have proved to be some of the most potent therapies for reducing elevated low-density lipoprotein (LDL) cholesterol and lessening the risk of coronary heart disease (CHD) and related events. Nonetheless, there are still questions about the clinical relevance of individual drug characteristics, such as chemical derivation, solubility ...
openaire +2 more sources

HMG-CoA Reductase Inhibitors

Reactions Weekly
Bansal AB, Cassagnol M.
europepmc +2 more sources

Predictive Modeling of HMG-CoA Reductase Inhibitory Activity and Design of New HMG-CoA Reductase Inhibitors. [PDF]